Diagnosis and treatment of antibody-mediated kidney allograft rejection

Transplant International

Volumn 16, Issue 11, 2003, Pages 773-787

  Böhmig, Georg ^a   Regele, Heinz ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antibody mediated rejection; Apheresis; C4d; Immunoadsorption; Kidney; Transplantation

Indexed keywords

15 DEOXYSPERGUALIN; ALLOANTIBODY; AZATHIOPRINE; COMPLEMENT COMPONENT C4D; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DONOR REACTIVE ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PROTEIN A; RITUXIMAB; STEROID; TACROLIMUS; ULEX EUROPAEUS AGGLUTININ; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; APHERESIS; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MORPHOMETRICS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ACUTE DISEASE; ANTIBODIES; BIOLOGICAL MARKERS; CHRONIC DISEASE; COMPLEMENT C4; COMPLEMENT C4B; GRAFT REJECTION; HUMANS; IMMUNOTHERAPY; KIDNEY; KIDNEY TRANSPLANTATION; PEPTIDE FRAGMENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0345530052     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00147-003-0658-3     Document Type: Review

References (121)

1. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts associated with preexisting humoral antibodies against donor cells. Lancet 1966; 1: 662-665.
2. Patel R, Terasaki PI. Significance of the positive test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
3. Wu A, Bühler LH, Cooper DKC. AB0-incompatible organ and bone marrow transplantation: current status. Transplant Int 2003; 16: 291-299.
4. Samstein B, Platt J. Physiologic and immunologic hurdles to xenotransplantation. J Am Soc Nephrol 2001; 12: 182-193.
5. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996; 50: 1464-1475.
6. Baldwin III WM, Halloran PF. Clinical syndromes associated with antibody in allografts. In: Racusen LC, Solez K, Burdick JF (eds) Kidney transplant rejection. Marcel Dekker, New York 1998; pp 127-147.
7. Crespo M, Delmonico F, Saidman S, et al. Acute humoral rejection in kidney transplantation. Graft 2000; 3: 12-17.
8. Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002; 11: 609-618.
9. Böhmig GA, Exner M, Watschinger B, Regele H. Acute humoral renal allograft rejection. Curr Opin Urol 2002; 12: 95-99.
10. Watschinger B, Pascual M. Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection. J Am Soc Nephrol 2002; 13: 2420-2423.
11. Jeannet M, Pinn VW, Flax MH, Winn HJ, Russel PS. Humoral antibodies in renal allotransplantation in man. New Engl J Med 1970; 282: 111-117.
12. Martin S, Dyer PA, Mallick NP, Gokal R, Harris R, Johnson RWG. Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation 1987; 44: 50-53.
13. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I response: I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990; 49: 85-91.
14. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response: II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550-555.
15. Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody: Analysis using the Banff grading schema. Transplantation 1996; 61: 1586-1592.
16. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319-326.
17. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464-470.
18. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338.
19. Racusen LC, Colvin RB, Solez K, et al. Antibody-Mediated Rejection Criteria - an Addition to the Banff '97 Classification of Renal Allograft Rejection. Am J Transplant 2003; 3: 708-714.
20. Lederer SR, Schneeberger H, Albert E, et al. Early renal graft dysfunction. The role of preformed antibodies to DR-typed lymphoblastoid cell lines. Transplantation 1996; 61: 313-319.
21. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214.
22. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59: 334-341.
23. Regele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16: 2058-2066.
24. Böhmig GA, Regele H, Exner M, et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12: 2482-2489.
25. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-658.
26. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582.
27. Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091-1099.
28. Herzenberg AM, Gill JS, Djurdjew O, Magil AB. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234-241.
29. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779-787.
30. Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242-251.
31. Regele H, Böhmig GA, Habicht A, et al. Capillary Deposition of Complement Split Product C4d in Renal Allografts is Associated with Basement Membrane Injury in Peritubular and Glomerular Capillaries: A Contribution of Humoral Immunity to Chronic Allograft Rejection. J Am Soc Nephrol 2002; 13: 2371-2380.
32. Haas M, Ratner LE, Montgomery RA. C4d staining of perioperative renal transplant biopsies. Transplantation 2002; 74: 711-717.
33. Baldwin III WM, Samaniego-Picota M, Kasper EK, et al. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation 1999; 68: 894-900.
34. Barrington R, Zhang M, Fischer M, Carroll MC. The role of complement in inflammation and adaptive immunity. Immunol Rev 2001; 180: 5-15.
35. Sund S, Hovig T, Reisaeter AV, Scott H, Bentdal O, Mollnes TE. Complement activation in early protocol kidney graft biopsies after living-donor transplantation. Transplantation 2003; 75: 1204-1213.
36. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int 2003; 63: 1888-1893.
37. Behr TM, Feucht HE, Richter K, et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies [In Process Citation]. J Heart Lung Transplant 1999; 18: 904-912.
38. Zwirner J, Felber E, Burger R, Bitter-Sauermann D, Riethmüller G, Feucht HE. Classical pathway of complement activation in mammalian kidneys. Immunology 1993; 80: 162-167.
39. Zwirner J, Felber E, Herzog V, Riethmüller G, Feucht HE. Classical pathway of complement activation in normal and diseased human glomeruli. Kidney Int 1989; 36: 1069-1077.
40. Karpinski M, Rush D, Jeffery J, et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 2807-2814.
41. Habicht A, Regele H, Exner M, et al. A case of severe C4d-positive kidney allograft dysfunction in the absence of histomorphologic features of rejection. Wien Klin Wochenschr 2002; 114: 945-948.
42. Segerer S, Böhmig GA, Exner M, et al. When allografts turn DARC. Transplantation 2003; 75: 1030-1034.
43. Böhmig GA, Regele H, Säemann MD, et al. Role of humoral immune reactions as target for antirejection therapy in recipients of a spousal-donor kidney graft. Am J Kidney Dis 2000; 35: 667-673.
44. Drachenberg CB, Steinberger E, Hoehn-Saric E, et al. Specificity of intertubular capillary changes: comparative ultrastructural studies in renal allografts and native kidneys. Ultrastruct Pathol 1997; 21: 227-233.
45. Gough J, Yilmaz A, Miskulin D, et al. Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens. Transplantation 2001; 71: 1390-1393.
46. Lajoie G. Antibody-mediated rejection of human renal allografts: an electron microscopic study of peritubular capillaries. Ultrastruct Pathol 1997; 21: 235-242.
47. Monga G, Mazzucco G, Messina M, Motta M, Quaranta S, Novara R. Intertubular capillary changes in kidney allografts: a morphologic investigation on 61 renal specimens. Mod Pathol 1992; 5: 125-130.
48. Yilmaz A, Yilmaz S, Kallio E, Rapola J, Hayry P. Evolution of glomerular basement membrane changes in chronic rejection. Transplantation 1995; 60: 1314-1322.
49. Takeuchi O, Oikawa T, Koyama K, et al. Multilayering of peritubular capillary is a specific diagnostic criterion for immunologic chronic rejection: does a humoral factor contribute to the pathogenesis of peritubular capillary lesions in chronic rejection? Transplant Proc 2000; 32: 306-307.
50. Abe M, Kawai T, Futatsuyama K, et al. Postoperative production of anti-donor antibody and chronic rejection in renal transplantation. Transplantation 1997; 63: 1616-1619.
51. Kerman RH, Susskind B, Kerman DH, et al. Anti-HLA antibodies detected in posttransplant renal allograft recipient sera correlate with chronic rejection. Transplant Proc 1997; 29: 1515-1516.
52. El Fettouh HA, Cook DJ, Bishay E, et al. Association between a positive flow cytometry crossmatch and the development of chronic rejection in primary renal transplantation. Urology 2000; 56: 369-372.
53. Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 2001; 71: 1106-1112.
54. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192-1194.
55. Baldwin III WM, Samaniego M, Qian Z, et al. Complement as a mediator of allograft injury: an inflammatory view. Transplantation Rev 2000; 14: 41-51.
56. Regele H, Böhmig GA. Tissue injury and repair in allografts: novel perspectives. Curr Opin Nephrol Hypertens 2003; 12: 259-266.
57. Brauer RB, Baldwin WM, 3rd, Ibrahim S, Sanfilippo F. The contribution of terminal complement components to acute and hyperacute allograft rejection in the rat. Transplantation 1995; 59: 288-293.
58. Qian Z, Hu W, Liu J, Sanfilippo F, Hruban RH, Baldwin WM, 3rd. Accelerated graft arteriosclerosis in cardiac transplants: complement activation promotes progression of lesions from medium to large arteries. Transplantation 2001; 72: 900-906.
59. Nakashima S, Qian Z, Rahimi S, Wasowska BA, Baldwin WM, 3rd. Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J Immunol 2002; 169: 4620-4627.
60. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994; 179: 985-992.
61. Kilgore KS, Schmid E, Shanley TP, et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997; 150: 2019-2031.
62. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185: 1619-1627.
63. Dobrina A, Pausa M, Fischetti F, et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in-vitro and in vivo. Blood 2002; 99: 185-192.
64. Colvin RB. Transplant Mac attack: humor the macrophages. Kidney Int 2003; 63: 1953-1954.
65. Wasowska BA, Qian Z, Cangello DL, et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 2001; 71: 727-736.
66. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-3814.
67. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807-1814.
68. Ren G, Hack BK, Minto AW, et al. A complement-dependent model of thrombotic thrombocytopenic purpura induced by antibodies reactive with endothelial cells. Clin Immunol 2002; 103: 43-53.
69. Sumitran-Holgersson S, Wilczek HE, Holgersson J, Soderstrom K. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002; 74: 268-277.
70. Marsh JE, Farmer CK, Jurcevic S, Wang Y, Carroll MC, Sacks SH. The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation 2001; 72: 1310-1318.
71. Hancock WW, Gao W, Shemmeri N, et al. Immunopathogenesis of accelerated allograft rejection in sensitized recipients: humoral and nonhumoral mechanisms. Transplantation 2002; 73: 1392-1397.
72. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582-587.
73. Opelz G. Collaborative transplant study - 10-year report. Transplant Proc 1992; 24: 2342-2355.
74. Cecka JM. The UNOS scientific renal transplant registry. Clin Transpl 1998; 1-16.
75. Cook DJ, Fettouh HI, Gjertson DW, Cecka JN. Flow cytometry cross-matching (FCXM) in the UNOS Kidney Transplant Registry. Clin Transpl 1998; 413-419.
76. Kerman RH, Susskind B, Buelow R, et al. Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection. Transplantation 1996; 62: 201-205.
77. Scornik JC, Salomon DR, Lim PB, Howard RJ, Pfaff WW. Posttransplant antidonor antibodies and graft rejection. Transplantation 1989; 47: 287-290.
78. Lobo PI, Spencer CE, Stevenson WC, Pruett TL. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995; 59: 357-360.
79. Monteiro F, Buelow R, Mineiro C, Rodriguez H, Kalil J. Identification of patients at high risk of graft loss by pre- and posttransplant monitoring of anti-HLA class I IgG antibodies by enzyme-linked immunosorbent assay. Transplantation 1997; 63: 542-546.
80. Christiaans MHL, Overhof-de Roos R, Nieman F, van Hooff JP, van den Berg-Loonen EM. Donor-specific antibodies after transplantation by flow cytometry. Transplantation 1998; 65: 427-433.
81. Kimikawa M, Tojimbara T, Nakajima I, et al. Posttransplant antidonor antibodies and chronic rejection in renal transplantation. Transplant Proc 1999; 31: 2872-2873.
82. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034-1040.
83. Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: 1460-1464.
84. Alarabi A, Backman U, Wikstrom B, Sjoberg O, Tufveson G. Plasmapheresis in HLA-immunosensitized patients prior to kidney transplantation. Int J Artif Organs 1997; 20: 51-56.
85. Haas M, Böhmig GA, Leko-Mohr Z, et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002; 17: 1503-1508.
86. Hickstein H, Korten G, Bast R, Barz D, Nizze H, Schmidt R. Immunoadsorption of sensitized kidney transplant candidates immediately prior to surgery. Clin Transplant 2002; 16: 97-101.
87. Hiesse C, Kriaa F, Rousseau P, et al. Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation. Nephrol Dial Transplant 1992; 7: 944-951.
88. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208-1211.
89. Kupin WL, Venkat KK, Hayashi H, Mozes MF, Oh HK, Watt R. Removal of lymphocytotoxic antibodies by pretransplant immunoadsorption therapy in highly sensitized renal transplant recipients. Transplantation 1991; 51: 324-329.
90. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 1531-1536.
91. Taube D. Immunoadsorption in the sensitized transplant recipient. Kidney Int 1990; 38: 350-358.
92. Soulillou JP, Guyot C, Guimbretiere J, et al. Plasma exchange in early kidney graft rejection associated with antidonor antibodies. Nephron 1983; 35: 158-162.
93. Allen N, Smith J, Tate D, Slapak M. Intensive plasma exchange in acute renal allograft rejection. Transplant Proc 1983; 15: 1061-1063.
94. Kirubakaran MG, Disney AP, Norman J, Pugsley DJ, Mathew TH. A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation 1981; 32: 164-165.
95. Bonomini V, Vangelista A, Frasca GM, di Felice A. Effects of plasmapheresis in renal transplantation. Trans ASAIO 1985; 31: 698-701.
96. Gannedahl G, Ohlmann S, Persson U, et al. Rejection associated with early appearance of donor-reactive antibodies after kidney transplantation treated with plasmapheresis and administration of 15-deoxyspergualin. Transplant Int 1992; 5: 189-192.
97. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
98. Sayegh MH, Colvin RB. Case record of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8-2003. A 35-year-old man with early dysfunction of a second renal transplant. N Engl J Med 2003; 348: 1033-1044.
99. Shimizu T, Tokiwa M, Yamaguchi Y. A case of acute antidonor antibody-mediated humoral rejection after renal transplantation with specific consideration of serial graft biopsy histology. Clin Transplant 2002; 16 (Suppl 8): 62-67.
100. Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 1490-1495.
101. Hickstein H, Korten G, Bast R, et al. Protein A immunoadsorption (IA) in renal transplantation patients with vascular rejection. Transfus Sci 1998; 19: 53-57.
102. Persson NH, Bucin D, Ekberg H, et al. Immunoadsorption in acute vascular rejection after renal transplantation. Transplant Proc 1995; 27: 3466.
103. Pretagostini R, Berloco P, Poli L, et al. Immunoadsorption with protein A in humoral rejection of kidney transplants. ASAIO J 1996; 42: M645-648.
104. Wang N, Lee JM, Tobiasch E, et al. Induction of xenograft accommodation by modulation of elicited antibody responses. Transplantation 2002; 74: 334-345.
105. Platt JL. C4d and the fate of allografts. J Am Soc Nephrol 2002; 13: 2417-2419.
106. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260-269.
107. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755.
108. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72: 419-422.
109. Casadei DH, del CRM, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 53-58.
110. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758-760.
111. Al-Uzri AY, Seltz B, Yorgin PD, Spier CM, Andreoni K. Successful renal transplant outcome after intravenous gamma-globulin treatment of a highly sensitized pediatric recipient. Pediatr Transplant 2002; 6: 161-165.
112. Zhang R, Szerlip HM. Reemergence of sucrose nephropathy: acute renal failure caused by high-dose intravenous immune globulin therapy. South Med J 2000; 93: 901-904.
113. Tsinalis D, Dickenmann M, Brunner F, Gurke L, Mihatsch M, Nickeleit V. Acute renal failure in a renal allograft recipient treated with intravenous immunoglobulin. Am J Kidney Dis 2002; 40: 667-670.
114. Plosker GL, Figgit DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and lymphocytic leukemia. Drugs 2003; 63: 803-843.
115. Edwards JC, Leandro MJ, Cambridge G. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans 2002; 30: 824-828.
116. Aranda JM, Jr., Scornik JC, Normann SJ, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 2002; 73: 907-910.
117. Garrett HE, Jr., Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of humoral rejection with rituximab. Ann Thorac Surg 2002; 74: 1240-1242.
118. Pierson RN, 3rd, Loyd JE, Goodwin A, et al. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation 2002; 74: 79-84.
119. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74: 1207-1210.
120. Alwayn IP, Xu Y, Basker M, et al. Effects of specific anti-B and/or antiplasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGa1 antibody. Xenotransplantation 2001; 8: 157-171.
121. Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72: 77-83.